ProPhase Labs, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
ProPhase Labs, Inc. (PRPH) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $35.13 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-29.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2023-03-29
- ProPhase Labs, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2021 was $35.13M.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|
| 2021-12-31 | $35.13M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |